First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Neal E ReadyClarisse Audigier-ValetteJonathan W GoldmanEnriqueta FelipTudor-Eliade CiuleanuMaría Rosario García CampeloKevin JaoFabrice BarlesiStéphanie BordenaveErika RijavecLaszlo UrbanJean-Sébastien AucoinCristina ZannoriKarim VermaelenOsvaldo Arén FronteraAlessandra Curioni FontecedroAmparo Sánchez-GastaldoOscar Juan-VidalHelena LinardouElena PoddubskayaDavid R SpigelSamreen AhmedMichele MaioSunney LiHan ChangJoseph FioreAngelic AcevedoLuis Paz-AresPublished in: Journal for immunotherapy of cancer (2023)
NCT02869789.